Omega-3D: Omega-3 for Diet-Driven Health Disparities

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

May 31, 2029

Study Completion Date

December 31, 2029

Conditions
Heart Health MarkersCardiovascular DiseasesOmega 3 Fatty Acids
Interventions
DIETARY_SUPPLEMENT

Omega-3 Fatty Acids

The oil-based supplements will include the Ultra Omega-3 product that delivers 683 mg EPA and 252 mg DHA (as ethyl esters) per capsule. A daily dose will provide 2.8 g of EPA+DHA (as ethyl esters). This product is part of the Nature Made line manufactured by Pharmavite (see Letter of Support). Three capsules will be self-administered orally by study participants, preferably at a single mealtime.

OTHER

Placebo

Safflower oil (placebo) that delivers 70-80% oleic acid and 10-14% LA. The placebo is identical in appearance and shape to the active study agent. Three capsules will be self-administered orally by study participants, preferably at mealtimes.

Trial Locations (2)

20057

Georgetown University, Washington D.C.

85721

School of Nutritional Sciences and Wellness, Tucson

All Listed Sponsors
collaborator

National Center for Complementary and Integrative Health (NCCIH)

NIH

collaborator

Georgetown University

OTHER

lead

University of Arizona

OTHER